JP2013516194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516194A5 JP2013516194A5 JP2012548181A JP2012548181A JP2013516194A5 JP 2013516194 A5 JP2013516194 A5 JP 2013516194A5 JP 2012548181 A JP2012548181 A JP 2012548181A JP 2012548181 A JP2012548181 A JP 2012548181A JP 2013516194 A5 JP2013516194 A5 JP 2013516194A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- nucleic acid
- promoter
- transduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29352210P | 2010-01-08 | 2010-01-08 | |
| US61/293,522 | 2010-01-08 | ||
| PCT/US2011/020578 WO2011085247A2 (en) | 2010-01-08 | 2011-01-07 | Vectors and methods for transducing b cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516194A JP2013516194A (ja) | 2013-05-13 |
| JP2013516194A5 true JP2013516194A5 (enExample) | 2014-02-27 |
| JP5873807B2 JP5873807B2 (ja) | 2016-03-01 |
Family
ID=44306176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548181A Active JP5873807B2 (ja) | 2010-01-08 | 2011-01-07 | Ｂ細胞を形質導入するためのベクターおよび方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9074223B2 (enExample) |
| EP (1) | EP2521789B1 (enExample) |
| JP (1) | JP5873807B2 (enExample) |
| CA (1) | CA2786664C (enExample) |
| DK (1) | DK2521789T3 (enExample) |
| ES (1) | ES2617749T3 (enExample) |
| WO (1) | WO2011085247A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014010823B1 (pt) * | 2011-11-07 | 2021-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial |
| US10240125B2 (en) * | 2013-03-14 | 2019-03-26 | Immusoft Corporation | Methods for in vitro memory B cell differentiation and transduction with VSV-G pseudotyped viral vectors |
| US20160075766A1 (en) | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
| CA2914595C (en) * | 2014-05-19 | 2022-12-13 | F. Hoffmann-La Roche Ag | Method for producing antibodies using ovine b-cells and uses thereof |
| DK3234107T3 (da) | 2014-12-19 | 2022-10-17 | Immusoft Corp | B-celler til in vivo-levering af terapeutiske midler |
| WO2016161446A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| CN109072192B (zh) * | 2016-02-16 | 2024-02-09 | 杜克大学 | 用于扩展和分化生产抗体的b细胞的方法 |
| WO2018201071A1 (en) * | 2017-04-27 | 2018-11-01 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents and dosages thereof |
| MX2020004063A (es) | 2017-10-20 | 2020-10-05 | Hutchinson Fred Cancer Res | Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados. |
| AU2019233929B2 (en) | 2018-03-16 | 2025-05-29 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
| RU2714380C1 (ru) * | 2018-12-28 | 2020-02-14 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ получения цитотоксических т-лимфоцитов, экспрессирующих химерные рецепторы |
| WO2022040202A1 (en) * | 2020-08-17 | 2022-02-24 | Northwestern University | B-cell based immunotherapy for the treatment of glioblastoma and other cancers |
| WO2025106856A1 (en) | 2023-11-15 | 2025-05-22 | Immusoft Corporation | Migratory modified differentiated b cells for cancer therapy |
| WO2025147573A2 (en) | 2024-01-05 | 2025-07-10 | Immusoft Corporation | Glp-1 expressing modified b cells for the treatment of metabolic disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| ES2430991T3 (es) * | 2000-06-01 | 2013-11-22 | Dnavec Research Inc. | Vector retroviral seudotipo que contiene proteína de membrana que tiene actividad hemaglutinina |
| WO2003068819A1 (en) * | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
| US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
| EP1975239A1 (en) | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
| EP2358868B1 (en) | 2008-11-21 | 2014-11-12 | California Institute of Technology | In vitro human b lymphopoiesis culture system |
-
2011
- 2011-01-07 EP EP11732231.3A patent/EP2521789B1/en active Active
- 2011-01-07 DK DK11732231.3T patent/DK2521789T3/en active
- 2011-01-07 JP JP2012548181A patent/JP5873807B2/ja active Active
- 2011-01-07 CA CA2786664A patent/CA2786664C/en active Active
- 2011-01-07 ES ES11732231.3T patent/ES2617749T3/es active Active
- 2011-01-07 WO PCT/US2011/020578 patent/WO2011085247A2/en not_active Ceased
- 2011-01-07 US US13/520,921 patent/US9074223B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516194A5 (enExample) | ||
| JP7551815B2 (ja) | Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製 | |
| US10829566B2 (en) | Method employing bispecific antibodies | |
| WO2015155370A4 (en) | Group b adenovirus modified in the e4orf4 region | |
| JP2019508017A5 (enExample) | ||
| JP2019534036A5 (enExample) | ||
| JP2012504959A5 (enExample) | ||
| JP2018509151A5 (enExample) | ||
| JP6683598B2 (ja) | 安定なトランスフェクトされた細胞を生成するための方法および組成物 | |
| WO2011085247A4 (en) | Vectors and methods for transducing b cells | |
| CN109306340B (zh) | 一种高效扩增全t细胞的人工抗原递呈细胞及其用途 | |
| US20230100000A1 (en) | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | |
| US20250297276A1 (en) | Macrophage-specific promoters and uses thereof | |
| JP2023532665A (ja) | 核酸の標的化組み込み | |
| CN112458116B (zh) | 一种pd-1敲除的cd19car-t细胞的构建方法 | |
| US20240415891A1 (en) | Activation responsive promoters and uses thereof | |
| JP2014530022A5 (enExample) | ||
| TW202400789A (zh) | Ｅｎｏ１基因的啟動子 | |
| JPWO2022214653A5 (enExample) | ||
| WO2025175182A1 (en) | Macrophage-specific promoters and uses thereof | |
| JP2024533328A (ja) | 誘導性プロモーター、それに基づくベクターおよび宿主細胞 | |
| WO2025006907A2 (en) | Improved multicistronic systems and uses thereof | |
| TW202540400A (zh) | 增強經工程改造之免疫細胞之細胞毒性的方法 | |
| WO2025080988A1 (en) | Engineered regulatory elements | |
| Ho et al. | Synthetic biology in immunotherapy and stem cell therapy engineering |